(Q95812285)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

title

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference

corrigendum / erratum

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)

0 references

9

Sadayoshi Ito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

author name string

Toshio Ogihara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Kenjiro Kikuchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hiroaki Matsuoka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Toshiro Fujita

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Jitsuo Higaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Masatsugu Horiuchi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Yutaka Imai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Tsutomu Imaizumi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hiroshi Iwao

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Kazuomi Kario

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Yuhei Kawano

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Shokei Kim-Mitsuyama

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Genjiro Kimura

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hiroaki Matsubara

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hideo Matsuura

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Mitsuhide Naruse

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Ikuo Saito

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Kazuyuki Shimada

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Kazuaki Shimamoto

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hiromichi Suzuki

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Shuichi Takishita

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Norio Tanahashi

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Takuya Tsuchihashi

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Makoto Uchiyama

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Shinichiro Ueda

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hirotsugu Ueshima

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Satoshi Umemura

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Toshihiko Ishimitsu

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Hiromi Rakugi

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

Japanese Society of Hypertension Committee

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

published in

Hypertension Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

page(s)

3-107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

30 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Current status of antihypertensive prescription and associated blood pressure control in Japan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

https://api.crossref.org/works/10.1038%2FHR.2009.163

1 reference

7 January 2021

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

7 January 2021

Identifiers

DOI

10.1038/HR.2009.163

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19300436%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference